【百济神州宣布塔拉妥单抗中国临床研究取得积极结果】5月26日,据百济神州公众号,该公司今日宣布其与安进公司在中国联合开展的注射用塔拉妥单抗2期临床研究DeLLphi-307已取得积极结果。

金融界
26 May
5月26日,据百济神州公众号,该公司今日宣布其与安进公司在中国联合开展的注射用塔拉妥单抗2期临床研究DeLLphi-307已取得积极结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10